anti-anti-coagulants

PhaseBio details dollars in AstraZeneca deal as it rolls out a plan for $86M-plus IPO
Endpoints
Mon, 09/24/18 - 09:44 am
PhaseBio
IPOs
PB2452
anti-anti-coagulants
AstraZeneca